Frequency, interobserver reproducibility and clinical significance of equivocal peaks in PCR clonality testing using Euroclonality/BIOMED-2 primers

Aims PCR studies for lymphoid clonality are now widely employed, especially using Euroclonality/BIOMED-2 primers. Criteria for interpretation as a clonal result, however, have proven controversial. This study examines the frequency and clinical significance of equivocal amplification patterns and measures the interobserver reproducibility of clonality interpretations. Methods At our institution, results of each primer set are first classified as clonal, non-clonal or abnormal (equivocal peak on polyclonal background). Final results for all primer sets are then collectively reported as positive (≥1 clonal result), negative (non-clonal results) or indeterminate (≥1 abnormal result) for a clonal population. Results of 274 consecutive clonality cases were reviewed, and the interobserver reproducibility of individual primer set reactions and final results was determined in a subset of 30 cases. Results 44/161 (27%) B-cell and 50/163 (31%) T-cell cases contained at least one abnormal peak. Of these, 29 (64%) and 31 (62%), respectively, showed clonal results in another primer set. Interobserver reproducibility was excellent for most primer sets and for final interpretations, but only fair to good for IGK V-J and TCRB D-J1+2 primer sets. A definitive diagnosis of lymphoma was rendered in 93%, 20% and 6% of B-cell cases and 90%, 42%, and 14% of T-cell cases positive, indeterminate or negative for a clonal population, respectively. Conclusions Using a subjective approach, abnormal (equivocal) peaks are frequently observed in routine practice. However, most cases with abnormal peaks contain clonal rearrangements in other primer sets, facilitating overall interpretation of final results with excellent interobserver reproducibility.

[1]  E. Schuuring,et al.  EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations , 2012, Leukemia.

[2]  A. Ariza,et al.  Improved clonality detection in Hodgkin lymphoma using the BIOMED‐2‐based heavy and kappa chain assay: a paraffin‐embedded tissue study , 2012, Histopathology.

[3]  R. Hamoudi,et al.  BIOMED‐2 PCR assays for IGK gene rearrangements are essential for B‐cell clonality analysis in follicular lymphoma , 2011, British journal of haematology.

[4]  T. Greiner,et al.  Assay design affects the interpretation of T-cell receptor gamma gene rearrangements: comparison of the performance of a one-tube assay with the BIOMED-2-based TCRG gene clonality assay. , 2010, The Journal of molecular diagnostics : JMD.

[5]  A. Molven,et al.  Detection of clonality in follicular lymphoma using formalin-fixed, paraffin-embedded tissue samples and BIOMED-2 immunoglobulin primers , 2010, Journal of Clinical Pathology.

[6]  K. Patel,et al.  Comparison of BIOMED-2 versus laboratory-developed polymerase chain reaction assays for detecting T-cell receptor-gamma gene rearrangements. , 2010, The Journal of molecular diagnostics : JMD.

[7]  J. Dongen,et al.  Immunoglobulin and T-cell receptor gene rearrangements , 2010 .

[8]  M. Stoler,et al.  Cell and tissue based molecular pathology , 2009 .

[9]  S. Serrano,et al.  FISH is better than BIOMED-2 PCR to detect IgH/BCL2 translocation in follicular lymphoma at diagnosis using paraffin-embedded tissue sections. , 2008, Leukemia research.

[10]  J. V. van Dongen,et al.  Immunoglobulin/T-cell receptor clonality diagnostics. , 2007, Expert opinion on medical diagnostics.

[11]  W. Erber,et al.  A practical strategy for the routine use of BIOMED‐2 PCR assays for detection of B‐ and T‐cell clonality in diagnostic haematopathology , 2007, British journal of haematology.

[12]  F. Kuo,et al.  A novel method for interpretation of T-cell receptor gamma gene rearrangement assay by capillary gel electrophoresis based on normal distribution. , 2007, The Journal of molecular diagnostics : JMD.

[13]  T. Molina,et al.  Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2007, Leukemia.

[14]  T. Molina,et al.  Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936 , 2007, Leukemia.

[15]  T. Molina,et al.  Improved reliability of lymphoma diagnostics via PCR-based clonality testing: — Report of the BIOMED-2 Concerted Action BHM4-CT98-3936 , 2007, Leukemia.

[16]  T. Molina,et al.  Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936 , 2007, Leukemia.

[17]  M. Werner,et al.  Application of BIOMED-2 primers in fixed and decalcified bone marrow biopsies: analysis of immunoglobulin H receptor rearrangements in B-cell non-Hodgkin's lymphomas. , 2005, The Journal of molecular diagnostics : JMD.

[18]  J. V. van Dongen,et al.  BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. , 2005, The Journal of molecular diagnostics : JMD.

[19]  J. Dongen,et al.  Validation of BIOMED-2 multiplex PCR tubes for detection of TCRB gene rearrangements in T-cell malignancies , 2004, Leukemia.

[20]  M Hummel,et al.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.

[21]  T. Greiner,et al.  Effectiveness of capillary electrophoresis using fluorescent-labeled primers in detecting T-cell receptor gamma gene rearrangements. , 2002, The Journal of molecular diagnostics : JMD.

[22]  Stephen S. Wilson,et al.  An automated semiquantitative B and T cell clonality assay. , 1999, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[23]  M. Gulley,et al.  Immunoglobulin and T-cell receptor gene rearrangement. , 1994 .

[24]  H. Griesser Applied Molecular Genetics in the Diagnosis of Malignant Non‐Hodgkin's Lymphoma , 1993, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[25]  M. Gulley,et al.  Classification and staging of lymphoma by molecular genetics , 1992 .

[26]  M. Gulley,et al.  Classification and staging of lymphoma by molecular genetics. , 1992, Cancer.